Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Research & Development: 2009-2024

Historic Research & Development for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $339.4 million.

  • Cytokinetics' Research & Development rose 17.28% to $99.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.3 million, marking a year-over-year increase of 22.52%. This contributed to the annual value of $339.4 million for FY2024, which is 2.81% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Research & Development is $339.4 million, which was up 2.81% from $330.1 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Research & Development ranged from a high of $339.4 million in FY2024 and a low of $97.0 million during FY2020.
  • Its 3-year average for Research & Development is $303.4 million, with a median of $330.1 million in 2023.
  • Data for Cytokinetics' Research & Development shows a peak YoY soared of 64.97% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Cytokinetics' Research & Development stood at $97.0 million in 2020, then surged by 64.97% to $159.9 million in 2021, then spiked by 50.57% to $240.8 million in 2022, then skyrocketed by 37.09% to $330.1 million in 2023, then rose by 2.81% to $339.4 million in 2024.